References
- Ruutu P, Valtonen V, Elonen E, Volin L, Tukiainen P, Ruutu T. Invasive pulmonary aspergillosis: A diagnostic and therapeutic problem. Scand J Infect Dis 1987; 19: 569–575
- Miller RP, Bates JH. Amphotericin B toxicity; a follow-up report on 53 patients. Ann Intern Med 1969; 71: 1089–1095
- Bennett JE. Flucytosine. Ann Intern Med 1977; 86: 319–322
- Troke PF, Andrews RJ, Marriot MS, Richardson K. Efficacy of fluconazole (UK-49, 858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother 1987; 19: 664–670
- Perfect JR, Durack DF. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985; 16: 81–86
- Sarani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31: 6–10
- Arudt C AS, Walsh TJ, McCully CL, Balis FM. Fluconazole penetrations for treating fungal infections of the central nervous system. J Infect Dis 1988; 157: 178–180
- Jevons S, Tarbit MH. The pharmacokinetics of UK-49, 858 in human volunteers. Zentralbl Bakteriol MikrobiolHyg 1986; 262: 152
- Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985; 28: 648–653
- Ikemoto HA. Clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989; 12: 2395–2475
- Vant Wout JW, Mattie H, van Furth RA. Prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988; 21: 665–672
- May RJ. The azole antifungal drugs. J Antimicrob Chemother 1987; 20: 1–5